舒尼替尼治疗晚期难治性非小细胞肺癌的临床疗效观察  

Clinical investigation of sunitinib in the treatment of advanced refractory non-small cell lung cancer

作　　者：刘俊[1] 韩宝惠[1] 姜丽岩[1] 金波[1] 王慧敏[1] 施春雷[1] 熊丽纹[1] 陈文怡[1] 王韡旻[1] 顾爱琴[1] 

机构地区：[1]上海交通大学附属胸科医院呼吸内科,上海200030

出　　处：《世界临床药物》2015年第10期674-678,共5页World Clinical Drug

基　　金：CSCO-t同辉"临床肿瘤学研究基金资助(编号:Y-H2010-041)

摘　　要：目的评价舒尼替尼治疗晚期难治性非小细胞肺癌（NSCLC）的临床疗效及安全性。方法 25例晚期NSCLC患者,既往均接受过含铂类方案化疗。用药方式为：50 mg口服,一日1次,连用4周后停药2周;不能耐受时减量至一日37.5 mg,持续给药。用药1个疗程后评价疗效,以后每2个疗程评价疗效。结果 1例（4%）患者达到部分缓解（PR）,13例（52%）患者在至少8周内达到稳定（SD）,11例（44%）患者在服药1月后出现进展（PD）。有效率（RR）为4%,疾病控制率（DCR）为56%,中位无疾病进展期（PFS）为10.1周（95%CI：7.6~12.5周）,中位总生存期（OS）为37.2周（95%CI：29.3~45.1周）,1年生存率为28%（7/25）。手足综合征、乏力及纳差是最常出现的不良反应,多为1-2级,患者耐受性良好。结论舒尼替尼单药治疗晚期难治性NSCLC具有一定疗效,且安全性好,对晚期难治性NSCLC的临床治疗潜力值得关注。Objective To evaluate the curative effect and adverse reactions of sunitinib in the treatment of advanced refractory non-small cell lung cancer（NSCLC）. Methods A total of 25 patients with advanced refractory NSCLC, who had ever experienced at least one regimen of chemotherapy or targeted therapy, received oral sunitinib 50 mg/d, for 4 weeks on treatment and followed 2 weeks without treatment. The effi cacy was evaluated at the end of 6-week cycle. Results Partial response was obtained in 1 patient（4%）. Thirteen patients（52%） achieved stable disease for at least 8 weeks. Progressive disease was seen in 11 patients（44%）. The response rate and disease control rate of the 25 patients were 4% and 56%, respectively. The median progression-free survival（PFS） was 10.1 weeks（95% CI： 7.6-12.5 weeks）, the median overall survival（OS） was 37.2 weeks（95% CI： 29.3-45.1 weeks） and the one year survival rate was 28%（7/25）. The treatment was generally well tolerated. The main adverse reactions included hand and foot syndrome, fatigue and anorexia. Conclusion Sunitinib, as a single drug, has a substantial effi cacy for patients with advanced refractory NSCLC.

关 键 词：舒尼替尼 非小细胞肺癌(NSCLC) 难治性 

分 类 号：R734.2[医药卫生—肿瘤] R979.19[医药卫生—临床医学]